Salzman C
Department of Psychiatry, Harvard Medical School, Boston, MA.
J Clin Psychiatry. 1988 Dec;49 Suppl:13-5.
The author reviews prior evidence and presents data from his prospective study comparing intramuscular lorazepam with intramuscular haloperidol for control of extreme, agitated psychotic behavior; the data demonstrate that lorazepam is effective and has fewer side effects than haloperidol. The effective intramuscular dose is 1 to 2 mg in conjunction with ongoing neuroleptic antipsychotic treatment. Lorazepam does not prevent future disruptive behavior, and data do not support its use as an agent for maintenance therapy.
作者回顾了先前的证据，并展示了他的前瞻性研究数据，该研究比较了肌肉注射劳拉西泮和肌肉注射氟哌啶醇对控制极端、激越性精神病行为的效果；数据表明，劳拉西泮有效，且副作用比氟哌啶醇少。在持续进行抗精神病药物治疗的同时，有效的肌肉注射剂量为1至2毫克。劳拉西泮不能预防未来的破坏性行为，且数据不支持将其用作维持治疗药物。
